MedTrace Logo

Photodynamic Therapy for PDA in NV AMD

NCT02452840 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-11-09

No results posted yet for this study

Summary

The purpose of this prospective observational study is to assess the potential clinical effects of adjunctive verteporfin photodynamic therapy (PDT) for persistent disease activity among patients with neovascular age-related macular degeneration (NV AMD). No specific interventions will occur as part of the study; participating subjects undergoing PDT as part of standard-of-care will be asked to consent to prospective collection of data from their medical records for up to five years from the date of consent, including results from ophthalmologic exams, imaging, and treatments. The primary study outcome will be the percentage of subjects with resolution of persistent disease activity at six months post-PDT treatment. Aside from a small risk of loss of confidentiality, risks associated with this study are no greater than those related to standard of care.

Conditions

  • Neovascular Age-related Macular Degeneration
  • Macular Degeneration

Interventions

OTHER

No Intervention

No Intervention

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    collaborator INDUSTRY

  • Duke University

    lead OTHER

Principal Investigators

  • Scott Cousins, MD · Duke University

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-11
Primary Completion
2019-02-28
Completion
2019-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02452840 on ClinicalTrials.gov